Nile Therapeutics, Inc (NLTX)
-OTC Markets 0.08 0.00(0.00%) 3:22PM EDT
| Prev Close: | 0.08 |
|---|
| Open: | 0.08 |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | 2.17 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.08 - 0.08 |
|---|
| 52wk Range: | 0.02 - 0.23 |
|---|
| Volume: | 19,800 |
|---|
| Avg Vol (3m): | 41,848 |
|---|
| Market Cap: | 3.57M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.10 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- NILE THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity SEDGAR Online(Thu, Mar 21)
- NILE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial StatemEDGAR Online(Mon, Nov 5)
- NILE THERAPEUTICS, INC. FinancialsEDGAR Online Financials(Tue, Aug 21)
- NILE THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Tue, Aug 14)
- NILE THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or PrinciEDGAR Online(Tue, Aug 7)
- NILE THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Thu, Jun 21)
- NILE THERAPEUTICS, INC. FinancialsEDGAR Online Financials(Thu, May 24)
- Nile Digs InZacks(Tue, May 15)
- NILE THERAPEUTICS, INC. Files SEC form 10-Q/A, Quarterly ReportEDGAR Online(Tue, May 15)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 2.97 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(0-00-31)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Nile Therapeutics, Inc., a development stage biopharmaceutical company, develops pharmaceutical products for the treatment of cardiovascular and renal diseases.
View More 
0.08%